Joseph E. Rowane, D.O. Home Address: 6073 Volkman Road Erie, PA 16506

Transcription

1 Joseph E. Rowane, D.O. Home Address: 6073 Volkman Road Erie, PA Professional Address: Chest Diseases of Northwestern PA 3580 Peach Street--Suite 103 Erie, Pennsylvania Phone: (814) PERSONAL: Date of Birth: April 5, 1964 Citizenship: USA Married: Christina Children: Alexa (1994), Ashlynn (1996), Lindsey (1999); Evan (2002) EMPLOYMENT: EDUCATION: Chest Diseases of NW PA 3580 Peach Street Suite 103A Erie, PA August 1, 1997 to Present Gannon University Erie, Pennsylvania B.S. in Science, 1986 Honors Dean s List (1986) University of Osteopathic Medicine and Health Sciences Des Moines, Iowa Doctor of Osteopathy, 1990 University of Osteopathic Medicine and Health Sciences, Undergraduate: Gannon University , B.S. INTERNSHIP: Cleveland Clinic Foundation Cleveland, Ohio Internal Medicine RESIDENCY: Cleveland Clinic Foundation Cleveland, Ohio Internal Medicine

2 FELLOWSHIP: Thomas Jefferson University Hospital Division of Pulmonary & Critical Care Pulmonary & Critical Care Medicine July July 1997 The Lakenau Hospital Department of Pulmonary Medicine Sleep Disorder Center July July 1997 CERTIFICATION & LICENSURE: 1994 Diplomat, American Board of Internal Medicine 1996 Diplomat, American Board of Internal Medicine, Pulmonary 1996 Pennsylvania License # OS L 1997 American Board of Internal Medicine, Critical Care Medicine 2011 American Board of Internal Medicine, Sleep Medicine SOCIETY MEMBERSHIPS: American College of Physicians American Medical Association American Thoracic Society American College of Chest Physicians Pennsylvania Thoracic Society Division Chief, Pulmonary Medicine, Hamot Medical Center AWARDS: Golden Apple, Distinguished Teachers Award at Saint Vincent Family Medicine 1998 Roland E. Miller Distinguished Teachers Award Hamot Medical Center Family Medicine 2001 Teacher of the Year Award, Hamot Medical Center 2002, 2004, 2008, 2010 Outstanding Clinical Educator, Saint Vincent Health Center 1998 PROFESSIONAL EXPERIENCE: Clinical Associate Staff Department of General Internal Medicine Cleveland Clinic Foundation

3 Associate Staff of Emergency Medicine Department of Emergency Medicine Cleveland Clinic Foundation Division Head of Pulmonary Medicine Hamot Medical Center present Clinical Pulmonary/Critical Care Medicine Saint Vincent Health Center present Hamot Medical Center present TB Clinician Erie County Health Department present Pulmonary/Critical Care Medicine Veterans Administration Medical Center present Co-Director of Saint Vincent Health Center Sleep Lab present PRESENTATIONS: Eosinophilic Granuloma And Other Interstitial Lung Diseases Presented to the Philadelphia Laennec Society of Medicine. March 12, 1996 Multidisciplinary Approach To The Care of The Pulmonary Critical Care Patient: Meeting Pulmonary Challenges Today and Tomorrow, Symposium for the Critical Care Nursing Continuing Education. Thomas Jefferson University. April 24, Asthma Diagnosis and Management. Presented to the Division of Medicine, Lankenau Hospital. December 11, Sleep Deprivation: From Internship to Sleep Apnea. Presented to the Practical Pulmonology Seminar. September 23, 1998.

4 Controversy of Antibiotic Use in Acute Exacerbation of COPD. Presented to the Practical Pulmonology Seminar. September 22, Where Does Volume Reduction Stand in the Role of the Patient with COPD? Presented to the Practical Pulmonology Seminar. September 20, 2000 RESEARCH EXPERIENCE: Pulmonary Research Fellow Thomas Jefferson University Hospital James E. Fish, MD; Director Stephen P. Peters, MD, Ph.D.: Associate Director Adept in: --Methacholine Challenge Testing --Antigen Whole Lung Challenge Testing --Bronchoscopic Segmental Antigen Challenge --Bronchoalveolar Lavage & Peripheral Blood Cell Separation by Density Gradient and Immunomagnetics --Gel Electrophoresis --Western Blot Analysis --Immunohistochemistry --ELLISA PUBLICATIONS: CHAPTERS: Rowane, J: Hemoptysis, in Rankel (ed); Saunders Manual of Medical Practice, 1st Edition, 1996 ABSTRACTS: Production of IL-8 By Peripheral Blood And BAL Eosinophils From Allergic Asthmatics. J. Rowane, J. Zangrilli, J.R. Shaver, S.K. Cho, F. Leone, J.E. Fish, S.P. Peters. Am J Resp Crit Care Med 153(4); A216, April The Use of a Formal Ethics Curriculum During Critical Care Fellowship Training: A National Survey. G.C. Kane, F.T. Leone, J.E. Rowane, J.E. Fish. Am J Resp Crit Care Med 153(4); A82, April 1996.

5 IL-10 Production by Alveolar Macrophages (M/M) in Asthmatic and Controls Following Segmental Antigen Challenge. J. Rowane, M. Pollice, F.T. Leone, J.E. Fish, S.P. Peters, Am J Resp Crit Care Med 155(4): A757, April 1997 STUDY TRIALS Pulmonary: 1. A Randomized, Double-Blind, Placebo-Controlled Parallel-Group, Multicenter Trial to Determine the Efficacy of Oral Zafirlukast (ACCOLATE) When Administered According to Current Labeling Instructions or Subjects With Asthma Receiving Inhaled B2-Agonist in Combination With Inhaled Corticosteroids (ICS). Sub-Investigator 2. A Randomized, Double-Blind, Double-Dummy, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Oral SB mg. Once Daily for 7 Days for the Treatment of Acute Exacerbation of Chronic Bronchitis. Sub-Investigator 3. A Randomized, Double-Blind, Multicenter Comparison of the Efficacy and Safety of Grepafloxacin (Raxar) in the Treatment of Patients with Community Acquired Pneumonia. Sub-Investigator 4. A 12-Week, Randomized, Double-Blind, Positive Control, Crossover Study of Albuterol, Ipratropium, and the Combination, as an Inhalation Solution in Patients with Chronic Obstructive Pulmonary Disease. Sub-Investigator 5. A Randomized, Double-Blind, Double-Dummy, Multicenter Parallel Group Study to Assess the Efficacy and Safety of Oral Augmentin SR, Two Tablets Equal to 2000/125 mg. Twice Daily for 7 Days Versus Oral Clarithromycin 500 mg. Twice Daily for 7 Days in the Treatment of Acute Exacerbation of Chronic Bronchitis. Sub-Investigator 6. An Open, Non Comparative Multicenter Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125 mg. Twice Daily for 7 Days for the Treatment of Bacterial Community Acquired Pneumonia in Adults. Sub- Investigator 7. A Randomized, Double-Blind, Double-Dummy, Multicenter, Parallel Group Study to Compare the Efficacy, Safety and Tolerability of Intravenous Gemifloxacin Followed by Oral

6 Gemifloxacin versus Intravenous Ceftriaxone Followed by Oral Levofloxacin in the Treatment of Nosocomial Pneumonia (NP) in Adults in Low Risk for Infection with Pseudomonas Aeruginosa. Sub-Investigator 8. A Randomized, Double-Blind, Double-Dummy, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Oral Gemifloxacin (Factive) 320 mg. Once Daily for 5 Days Versus Oral Levofloxacin 500 mg. Once Daily for 7 Days for the Treatment of Acute Exacerbations of Chronic Bronchitis. Sub-Investigator. 9. A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Investigate the Long-Term Effects of Salmeterol/Fluticasone Propionate 50/500ug bd, Salmeterol 50ug bd and Fluticasone Propionate 500ug bd, All Delivered via the Diskus/Accuhaler Inhaler, on the Survival of Subjects with Chronic Obstructive Pulmonary Disease Over 3 Years of Treatment. Sub-Investigator 10. A Randomized, Double-Blind, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125 mg Twice Daily for 5 Days Versus 7 Days in the Treatment of Adults with Acute Exacerbations of Chronic Bronchitis. Sub-Investigator 11. A Placebo-Controlled Comparison of the Efficacy and Safety of the Current US Version of Pulmicort Turbuhaler and The New Version of Pulmicort Turbuhaler in Asthmatic Adults and Adolescents Currently Treated with Inhaled Steroids. Sub-Investigator 12. A Randomized, 12-week, Double-blind, Placebocontrolled, parallel-group Pilot Study to Evaluate the Safety and Additional Efficacy of Adding Cilomilast (ARIFLO) 15 mg. Twice Daily to Treatment with ADVAIR 250/50 Twice Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD). 13. A 52-week, randomized, double-blind, single-dummy, parallel group, multicenter Phase III study comparing the long-term safety of SYMBICORT pmdi 160/4.5 ug x 4 actuations twice daily to SYMBICORT pmdi 160/4.5 ug x 2 actuations twice daily and budesonide HFA pmdi 160 ug x 4 actuations twice daily in adult and adolescent subjects with asthma. (Protocol: 0728)

7 14. A Placebo-Controlled Comparison of Efficacy and Safety of the Current US Version of Pulmicort (Budesonide) Turbuhaler and the New Version of Pulmicort Turbuhaler in Asthmatic Adults Currently Treated with Inhaled Steroids. (Protocol: 0620). 15. A Twelve-Week, Randomized, Double-Blind, Double- Dummy, Placebo and Active Controlled Study of SYMBICORT pmdi Administered Once Daily in Adults and Adolescents with asthma. (Protocol: 0726). 16. A Long Term Safety Study of Levalbuterol and Racemic Albuterol in Sujbects Twelve Years of Age and Older with Asthma. (Protocol: ). 17. A Randomized, 24-week, Double-blind, Placebocontrolled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO (15 mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD). (Protocol: CIL103657) 18. A Randomized, Double-Blind, Parallel Group, 52-week Study to Compare the Effect of the Fluticasone Propionate/Salmeterol Diskus Combination Product 250/50 mcg BID with Salmeterol Diskus 50 mcg BID on the Annual Rate of Moderate/Severe Exacerbations in Subjects with COPD. (Protocol: SCO100250) 19. A 6-Month Double-Blind, Double-dummy, Randomized, Parallel Group, Multicenter Efficacy and Safety Study of Symbicort pmdi 2 x 160/4.5 mg bid and 2 x 80/4.5 mg bid Compared to Formoterol TBH, Budesonide pmdi (& the combination) & Placebo in COPD patients. (protocol: D5899C00002) 20. A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 30-Night Polysomnographic Study of MK-0928 in Elderly Patients with Primary Insomnia. (protocol: MK-0928) 21. A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 30-Night Polysomnographic Study of MK-0928 in Adult Patients with Primary Insomnia. (protocol: MK-0928) 22. A 26-week treatment, multi center, randomized, doubleblind, double dummy, placebo-controlled, adaptive, seamless, parallel-group study to assess the efficacy, safety and tolerability of two doses of indacaterol (selected from 75, 150, 300 & 600 ug o.d.) in patients with chronic

8 obstructive pulmonary disease using blinded formoterol (12 ug b.i.d.) and open label triotropium (18 ug o.d.) as active controls. (Protocol No.: CQAB149B2335S) 23. A 12-week treatment, multi center, randomized, doubleblind, placebo controlled, parallel group study to assess the efficacy and safety of indacaterol (150 ug o.d.) in patients with chronic obstructive pulmonary disease. (Protocol No.: CQAB149B2346) 24. A Phase IIb clinical trial to evaluate the safety, tolerability and immunogenicity of Zoster vaccine in patients on chronic/maintenance corticosteroids. (Protocol No.: V ) 25. A randomized, double-blind, parallel group 12-week comparison of the efficacy and safety of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a metered-dose-inhaler 230/42 mcg twice-daily with Fluticasone Propionate/Salmeterol DISKUS 250/50 mcg twice-daily in subjects with COPD. (Protocol No.: ADC ) 26. A double-blind, randomized, placebo-controlled, multi center, parallel group, dose-ranging study of MK-0633 in adult patients with Chronic Asthma. (Protocol No.: ) 27. A 52-week, randomized, double-blind, parallel-group study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects with Asthma (Protocol: ADA109057) 28. A multicenter, randomized, double-blind, placebocontrolled, parallel group, 4-week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat inhaled doses of the Combination of GSK and GW administered once-daily in Subjects With COPD (Protocol: DB ) 29. A randomized, double-blind, parallel-group, 24-week study to evaluate the efficacy and safety of ADVAIR DISKUS (Fluticasone Propionate/Salmeterol Combination Product 250/50 mcg Inhalation Powder) BID plus Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder 18mcg) QD versus Spiriva QD plus Placebo DISKUS BID

9 in Subjects with Chronic Obstructive Pulmonary Disease (COPD) (Protocol: ADC111114) 30. A randomized, double-blind, controlled, parallel group, 12 week treatment study to compare the efficacy and safety of the combination of indacaterol 150 µg once daily with open label tiotropium 18µg once daily versus open label tiotropium 18µg once daily in patients with moderate-tosevere chronic obstructive pulmonary disease (Protocol No.: CQAB149B2351) 31. Efficacy and safety of aclidinium bromide at two dose levels (200 µg twice daily, 400µg twice daily) vs. placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD) (Protocol: LAS-MD-33) 32. A Long-term, Randomized, Double-Blind, Extension Study of the Safety, Tolerability and Efficacy of Aclidinium Bromide at Two Dose Levels When Administered to Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (Protocol: LAS-MD-36) 33. A randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of 2 doses of aclidinium bromide compared with placebo for 12 weeks in patients with moderate to severe, stable chronic obstructive pulmonary disease followed by a 40-week evaluation of the 2 aclidinium bromide doses (Protocol LAS-MD-38) 34. Validation of a New Shortness of Breath with Daily Activities Questionnaire in patients with Chronic Obstructive Pulmonary Disease (ASQ112989) 35. Novartis Pharmaceuticals trial entitled: A randomized, double-blind, double-dummy, placebo-controlled, parallelgroup study to assess the efficacy and safety of different doses of indacaterol in adult patients with persistent asthma, using salmeterol as an active control.cqab149b Novartis Pharmaceuticals trial entitled: A 26-week treatment multicenter, randomized, double-blind, parallelgroup, placebo and active controlled (open label) study to assess the efficacy, safety and tolerability of QVA149 (110/50 mcg q.d.) in patients with moderate to severe chronic obstructive pulmonary disease (COPD). QVA149A2303

10 37. A 52-week treatment, multi-center, randomized, doubleblind, parallel-group, active controlled study to evaluate the effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and open-label tiotropium (18 μg o.d.) on COPD exacerbations in patients with severe to very severe chronic obstructive pulmonary disease (COPD). CQVA149A A randomized, active-controlled, double-blind, doubledummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution delivered by the Respimat Inhaler with Tiotropium inhalation capsules 18 µg delivered by the HandiHaler A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK mcg once-daily alone and in combination with GW mcg oncedaily via novel Dry Powder Inhaler (ndpi) in Subjects with Chronic Obstructive Pulmonary Disease (COPD). DB A 24-Week, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW Inhalation Powder and the Individual Components Delivered Once-Daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease: DB A Phase III, Randomized, Double-blind, Placebo- Controlled Study Evaluating The Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo for 24- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD): LAC-MD-31.

11 42. A Long-Term, Randomized, Study of the Safety and Tolerability of a Fixed-Dose Combination of Aclidinium Bromide/Formoterol Fumarate compared with Formoterol Fumarate in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD): LAC- MD A 52-week, double-blind, randomized, placebo controlled parallel group study to evaluate the effect of roflumilast 500 μg on exacerbations in severe to very severe COPD patients treated with fixed dose combination LABA/ICS (Advair 250/50 μg or, Symbicort 160/4.5 μg): ROF-MD A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or an increased risk for cardiovascular disease: HZC SUMMIT. 45. Novartis Pharmaceuticals trial entitled: A randomized, placebo-controlled, dose-ranging, multi-centre trial of QAW039 (1-450 mg p.o.) to investigate the effect on FEV 1 in and ACQ patients with moderate-to-severe, persistent, allergic asthma, inadequately controlled with ICS therapy: CQAW039A A Phase III, Long-Term, Randomized, Double-Blind, Extension Study of the Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients with Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD): LAC- MD A randomized, double blind, parallel group study to assess the efficacy and safety of 12 weeks of once daily, orally inhaled, co-administration of olodaterol 5µg (delivered by the Respimat Inhaler) and tiotropium 18µg (delivered by the HandiHaler ) compared to once daily, orally inhaled, co-administration of placebo (delivered by the Respimat Inhaler) and tiotropium 18µg (delivered by the HandiHaler ) in patients with Chronic Obstructive Pulmonary Disease (COPD): Revised 1/13

12